Pharmaceutical

STAT+: Pharmalittle: Merck sues U.S. to halt Medicare d...

Merck sued the U.S. government, seeking an injunction to block the drug-price ne...

STAT+: Novocure’s electric fields device prolongs survi...

Oncologists accustomed to treating cancer with medicines have been slow to turn ...

STAT+: Medicare taps acting official to head up its new...

Medicare has chosen a career official to temporarily lead its implementation of ...

Academia’s postdoc system is teetering, imperiling effo...

New life science Ph.D. graduates who have kids or big loans, or are Black or fem...

STAT+: The woman behind AstraZeneca’s cancer winning st...

“Seeing a drug emerge is one of the most exciting things that you can do,” said ...

Opinion: When should hospitals require masks?

There are scenarios where the benefits of masking in health care settings would ...

Opinion: Four communication lessons we learned the hard...

The first lesson we learned the hard way during the pandemic: Don't assume scien...

STAT+: More than 200 FDA staffers have retired in less ...

More than 230 people have retired from the FDA since Oct. 1.

Watch: Why do we get seasonal allergies?

Why do we get seasonal allergies? And why do they make us so miserable? STAT exp...

STAT+: FDA removes neurologist with financial ties to E...

The FDA has removed a neurologist with financial ties to Biogen and Eisai from a...

STAT+: FDA oncology head wants advisory panels to keep ...

“I think we need to vote," said the FDA's oncology chief, Richard Pazdur. "We ha...

STAT+: UnitedHealth starts bidding war with $3.3 billio...

UnitedHealth Group and its Optum division proposed to buy Amedisys for $3.3 bill...

STAT+: Ted Love, BIO’s first Black board chair, aims to...

“It's not just about profits. It certainly is not about us as individuals. It's ...

STAT+: Gilead’s CAR-T therapy prolongs survival in key ...

Proving a meaningful survival benefit for patients with a type of blood cancer r...

STAT+: Bellerophon Therapeutics trial fails despite inn...

The failure of Bellerophon Therapeutics' study serves as an important reminder t...

STAT+: FDA will allow troubled chemotherapy maker to re...

"It’s nerve wracking — his company runs a factory that made a significant portio...